9900532-4
IPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/12, 9/72

A1

(11) International Publication Number: WO 98/56349

(43) International Publication Date: 17 December 1998 (17.12.98)

(21) International Application Number: PCT/EP98/03533

(22) International Filing Date: 10 June 1998 (10.06.98)

(30) Priority Data:
9712434.1 13 June 1997 (13.06.97) GB

(71) Applicant *(for all designated States except US)*: CHIESI FARMACEUTICI S.P.A. [IT/IT]; Via Palermo, 26/A, I–43100 Parma (IT).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: LEWIS, David [GB/IT]; Via Palermo, 26/A, I–43100 Parma (IT). GANDERTON, Davis [GB/IT]; Via Palermo, 26/A, I–43100 Parma (IT). MEAKIN, Brian [GB/IT]; Via Palermo, 26/A, I–43100 Parma (IT). VENTURA, Paolo [IT/IT]; Via Palermo, 26/A, I–43100 Parma (IT). BRAMBILLA, Gaetano [IT/IT]; Via Palermo, 26/A, I–43100 Parma (IT). GARZIA, Raffaella [IT/IT]; Via Palermo, 26/A, I–43100 Parma (IT).

(74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I–20122 Milano (IT).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PHARMACEUTICAL AEROSOL COMPOSITION

(57) Abstract

A composition for use in an aerosol inhaler comprises an active material, a propellant containing a hydrofluoroalkane and a cosolvent. The composition further includes a low volatility component which is added to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler. With the addition of the low volatility component, the MMAD of the aerosol particles may be comparable to the MMAD of aerosol particles of an aerosol inhaler including CFC as propellant.